Eli Lilly Says Phase 3 Trial of Tirzepatide Met Primary, Secondary Endpoints
Eli Lilly's Muvalaplin Shows Positive Phase 2 Results in Reducing Heart Disease Risk Factor
Makers of Weight-Loss Drugs Want Your Employer to Pay for Them -- WSJ
Eli Lilly and Co (LLY.US) has a potential first-in-class oral small molecule that significantly reduces Lp(a) levels in adults at high risk of cardiovascular events.
Ruth Gimeno, Vice President of eli lilly and co Diabetes and Metabolism Research Group, said: "We are pleased to see these promising results and look forward to further exploring the next steps of muvalaplin's development."
Evercore Maintains Eli Lilly and Co(LLY.US) With Hold Rating
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,010
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}